We are 225,770 members in 82 forums discussing 158,444 topics.

Help with Abbreviations

Topic: The CONTESSA study is enrolling! Advanced-stage, HR+, HER2-

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Jun 1, 2018 06:33PM - edited Jun 2, 2018 02:00PM by Moderators

Moderators wrote:

The CONTESSA study is looking to see if tesetaxel, an experimental taxane chemotherapy medicine that is taken orally as a pill, in combination with a lower-than-usual dose of Xeloda (chemical name: capecitabine) is better than the standard dose of Xeloda alone. Xeloda also is taken orally as a pill.

The CONTESSA study is being conducted at multiple sites around the world, including in the United States, the United Kingdom, Australia, France, Germany, Italy, Spain, and Russia.

For more information or to enroll, visit the CONTESSA Trial page on Breastcancer.org:http://www.breastcancer.org/treatment/clinical_trials/featured/contessa.

People are eligible to participate in the CONTESSA trial if they:

  • have been diagnosed with hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
  • were treated with a taxane before or after breast cancer surgery for an earlier stage of breast cancer
  • were treated with any number of hormonal therapy medicines
  • were treated with any number of targeted therapy medicines, such as Ibrance (chemical name: palbociclib) or Afinitor (chemical name: everolimus)
  • have received no chemotherapy to treat the locally-advanced or metastatic disease
    OR received one chemotherapy regimen that did not include a taxane or Xeloda to treat the locally advanced or metastatic disease
To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply